# Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct06347003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06347003](<https://clinicaltrials.gov/study/NCT06347003>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06347003

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.

## Technical summary

Registry record NCT06347003. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-22 (actual); primary completion 2026-06-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 446 participants (enrolled count; ClinicalTrials.gov record NCT06347003, source copy `cardio:ctgov-nct06347003-2026-10-08`, retrieved 2026-11-18)
- Started: 2024-07-22 (actual) (ClinicalTrials.gov record NCT06347003, source copy `cardio:ctgov-nct06347003-2026-10-08`, retrieved 2026-11-18)
- Primary completion: 2026-06-12 (actual) (ClinicalTrials.gov record NCT06347003, source copy `cardio:ctgov-nct06347003-2026-10-08`, retrieved 2026-11-18)
- Completion: 2026-08-25 (actual) (ClinicalTrials.gov record NCT06347003, source copy `cardio:ctgov-nct06347003-2026-10-08`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; China; Croatia; Czechia; Hungary; Italy; Poland; Romania; Slovakia; Spain; United Kingdom (ClinicalTrials.gov record NCT06347003, source copy `cardio:ctgov-nct06347003-2026-10-08`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06347003-2026-10-08`, retrieved 2026-11-18)

## The registry's words

- Brief title: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
- Acronym: SHASTA-3
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): Plozasiran Injection
- Intervention (Drug): Placebo
- Lead sponsor: Arrowhead Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Arrowhead Pharmaceuticals (`cardio:org-arrowhead-pharmaceuticals`)

## Provenance

Content hash: 1910cf8efdc5dc8bc9cb3aad3b6dcfb4c0df32ce704f974077a0a786f3ff32c4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
